Technology

& Pipeline

Technology

& Pipeline

Pipeline

Immunocore has a robust pipeline of wholly-owned and partnered programmes.

Alongside high value proprietary programmes, Immunocore has co-discovery and co-development programmes with Lilly and discovery programmes, including milestones and royalties, with Genentech, GlaxoSmithKline and AstraZeneca (MedImmune). 

 
 
Stage
 

Product

Indication
ImmTAC generation
IND
enabling

Phase I

Phase II

Pivotal
Owner /
Collaborator
IMCgp100
Uveal melanoma

IMCgp100 checkpoint combination
Cutaneous melanoma

IMCgp100 SMI combination
Uveal melanoma

GSK #1
NSCLC / Bladder cancer / Synovial sarcoma

IMC-C103C
Lung / Head & Neck / Oesophageal

IMC-D104C
Lung / Ovarian / Breast / Endometrial

Additional oncology programmes
Various

Partnered oncology programmes
Various

Infectious disease programmes
Various

Autoimmune programmes
Various